Human papillomavirus vaccine recombinant bivalent - Japan Vaccine/MedImmune

Drug Profile

Human papillomavirus vaccine recombinant bivalent - Japan Vaccine/MedImmune

Alternative Names: Cervarix; GSK-580299; HPV-16/18 vaccine - Japan Vaccine; Human papillomavirus (types 6, 18) L1 virus-like particle vaccine - Japan Vaccine; Human Papillomavirus 16/18 L1 AS04 virus-like particle cervical cancer vaccine - Japan Vaccine; Human papillomavirus bivalent (types 16, 18) recombinant vaccine - Japan Vaccine; MEDI 517; MEDI-517 HPV-16/18 VLP AS04 vaccine

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections

Most Recent Events

  • 28 Feb 2018 GlaxoSmithKline initiates enrolment in a phase III follow-up trial of NCT00996125) for human papillomavirus prevention (In volunteers; In adolescents, In adults, In the elderly) in China (NCT03355820)
  • 28 Nov 2017 GlaxoSmithKline plans a phase III extension study of the HPV-058 study for Cervical Intraepithelial Neoplasia in January 2018 , (NCT03355820)
  • 23 Nov 2017 GlaxoSmithKline completes a phase III trial in Human papillomavirus infections in USA and Canada (IM) (NCT01190189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top